Effect of Metformin Treatment on Gonadotropin Levels in Women With Polycystic Ovary Syndrome: A Systematic Review and Meta‐Analysis of 51 Randomised Controlled Trials
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
ABSTRACT Aims This study aimed to explore the impact of metformin on gonadotropin levels in women with polycystic ovary syndrome (PCOS) based on a meta‐analysis of randomised controlled trials (RCTs). Methods The search process was performed in PubMed, Scopus, Web of Science, ClinicalTrials.gov and Google Scholar. RCTs were eligible for meta‐analysis if they had a parallel or crossover design and reported gonadotropin levels before and after metformin treatment. A random‐effects model and the generic inverse variance method were used for meta‐analysis. Results The meta‐analysis of 51 RCTs, 48 of which included only and 2 included predominantly women with PCOS, showed that metformin treatment did not affect FSH (WMD: −0.22 IU/L, 95% CI: −0.54, 0.11, p = 0.19, I 2 = 84%) or LH (WMD: 0.11 IU/L, 95% CI: −0.38, 0.60, p = 0.66, I 2 = 75%), but it significantly increased the LH/FSH ratio (WMD: 0.24%, 95% CI: 0.06, 0.43, p = 0.01, I 2 = 93%). Additionally, the effect size was sensitive to one study for FSH, LH and LH/FSH ratio following the sensitivity analysis. Conclusion Our meta‐analysis, the largest one conducted to date, indicates that metformin does not significantly affect circulating gonadotropin levels in reproductive‐age women with PCOS.
Fields of Study & Subjects
Ovarian function and disorders
Diabetes
Cardiovascular Risks
and Lipoproteins
Reproductive Biology and Fertility
Publication details
- Journal / source
- Diabetes Obesity and Metabolism
- Volume
- 28
- Issue
- 6
- Pages
- 4573–4586
- Publication date
- 27 March 2026
- Language
- EN